PMC

Bromocriptine (Bromo) improves glucose tolerance in diet-induced obese (DIO) male mice. A: Bromo treatment (solid line) in DIO male mice improves glucose clearance compared with vehicle (dashed line) in response to a glucose tolerance test (2 mg/kg). Repeated-measures ANOVA with a Tukey’s multiple-comparison test. Gray asterisk corresponds to the significance between the male DIO wild-type (WT) vehicle and Bromo treatment. B: corresponding area under the curve (AUC) in vehicle-treated (open bars) and Bromo-treated (black bars) DIO and lean male mice. *P < 0.05, **P < 0.01, and ****P < 0.0001; 1-way ANOVA with a Tukey’s multiple-comparison test. C: Bromo treatment (solid line) in female mice has no effect on glucose clearance compared with vehicle (dashed line) in response to a glucose tolerance test (2 mg/kg) in both high-fat diet (HFD) and lean groups. Repeated-measures ANOVA with a Tukey’s multiple-comparison test. D: corresponding AUC in vehicle-treated (open bars) and Bromo-treated (black bars) in both DIO and lean female mice; 1-way ANOVA with a Tukey’s multiple-comparison test. E: fasting serum insulin for both lean and DIO male and female mice. Bromo (black bars) and vehicle treatment (open bars); 2-way ANOVA with a Sidak’s multiple-comparison test. F: Bromo (black bars) did not lead to weight loss in DIO, lean, male, or female mice. *P < 0.05, **P < 0.01; 2-way ANOVA with a Tukey’s multiple-comparison test. (Male mice: DIO treated with Bromo, n = 6; DIO treated with vehicle, n = 4; lean treated with Bromo, n = 3; lean treated with vehicle, n = 2). (female mice: DIO treated with Bromo, n = 6; DIO treated with vehicle, n = 3; lean treated with Bromo, n = 4; lean treated with vehicle, n = 4). G: DIO male mice treated with Bromo did not differ in their daily food intake from vehicle-treated mice. Repeated-measures ANOVA (n = 8 DIO male mice treated with Bromo; n = 6 DIO male mice treated with vehicle).

Hydrophobic nucleobase analogs: 7-propynyl isocarbostyril nucleoside (dPICS) []; isocarbostyril nucleoside (ICS); 3-methylnaphthalene (3MN); azaindole (7AI) []; bromo phenyl derivatives at positions 2, 3, and 4 (2Br, 3Br, and 4Br, resp.); cyano derivatives at positions 2, 3, and 4 (2CN, 3CN, and 4CN, resp.), fluoro derivatives at positions 2 and 3 (2FB, 3FB, resp.) [].

Equatorial location of hydroxy group in lactone 6 as the stereochemical consequence of microbial hydrolytic dehalogenation of chloro- (3), bromo- (4) and iodolactone (5) proceeding with the inversion at C-2.

Structure of SN56, [³H]-SN56 and its bromo precursor 4.